Pseudoephedrine: risk of PRES/RCVSThe European Pharmacovigilance Risk Assessment Committee reviewed reported cases and post-marketing safety data to evaluate the risks of PRES and RCVS with pseudoephedrine-containing medicines. Drug News—September 2024A review of new launches, new indications, new dosage forms and Health Canada advisories. NEW PRODUCT: Noyada Get the info you need on this new product, part of our drug news roundup for September. Precipitous withdrawal? Research shows risk is low with buprenorphine for treating opioid use disorder Fears of severe reaction to the drug have prevented some providers from prescribing it, but appear to be unwarranted. How antibiotics administered to newborns transform immunity into allergy Researchers at the University of British Columbia have identified the cellular and molecular mechanisms, induced by a class of antibiotics, that can lead to respiratory allergies. Pharmacist-led interventions focusing on improper medication disposal are lacking Systematic review examines pharmacist-led interventions that address improper disposal practices of unused and expired household medications. Seven new indications for drugs doctors and pharmacists should know about Get the info you need on this on new indications for seven existing drugs, part of our drug news roundup for September. POP QUIZ: SGLT2 Inhibitors and surgery How carefully did you read this recent Health Canada safety review? NEW DRUG: Ebglyss for atopic dermatitis Get the info you need on this new product, part of our drug news roundup for September. Efficacy and safety of skeletal muscle relaxants used long term for chronic pain Systematic review examines the effectiveness and adverse effects of long-term use of skeletal muscle relaxants for chronic pain. First Previous 10 11 12 13 14 Next Last
